8.922EUR-2.06%Mkt Cap: 6.60B $P/E: 14.631d ago
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates thr…
Industry Peers
Drug Manufacturers - Generalvs Drug Manufacturers - General
P/E
Cheaper
P/B
Cheaper
Div Yield
Higher
1M Perf
Higher
$1.07TUSDP/E 42.6
$611.36BUSDP/E 29.4
$444.21BUSDP/E 123.9
$308.01BUSDP/E 21.1
$317.37BUSDP/E 36.2
$281.52BUSDP/E 22.5
$275.65BUSDP/E 22.4
$269.91BUSDP/E 28.1
$237.69BUSDP/E 28.0
$202.85BUSDP/E 11.5
$195.44BUSDP/E 25.2
$156.86BUSDP/E 17.2
$137.24BUSDP/E 18.4
$117.66BUSDP/E 16.1
$97.68BUSDP/E 19.0
$86.27BUSDP/E 14.0
$51.69BUSD
$31.90BUSDP/E 23.3
MRV
Marvell Technology, Inc.$30.93BUSDP/E 11.7
$11.35BUSDP/E 22.7
$11.02BUSDP/E 19.1
$10.98BUSDP/E 19.1
$3.56BUSDP/E 14.6
$3.03BUSDP/E 18.5
$54.86MUSD
$39.77MUSD
ELXR
Elixxer Ltd.$9.51MUSD
ROSE
DocMorris AG—
PHOO
Photocure ASA—
FLXN
Horizon Flexible Income ETF—P/E 27.2
CELG-RI
Bristol-Myers Squibb Company Ce—
Indicators:|
Key Statistics
Company
Market Cap6.60B $
Enterprise Value18.97B $
Revenue (TTM)8.08B $
Gross Profit3.11B $
Net Income (TTM)436.96M $
Revenue/Share11.88 USD
Last Price8.922 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees25.0K
CountryES
SectorHealthcare
IndustryDrug Manufacturers - General
ISIN—
Valuation
P/E (Trailing)14.63
P/E (Forward)8.06
PEG0.24
EV/EBITDA10.41
EV/Revenue2.35
P/S0.82
P/B1.12
EPS (TTM)0.61
EPS (Forward)1.11
52W Range
8.4329% of range13.70
52W High13.70 EUR
52W Low8.432 EUR
Profitability
Gross Margin38.00%
Oper. Margin16.47%
EBITDA Margin22.54%
Profit Margin5.34%
ROE7.63%
ROA2.04%
Growth
Revenue Growth-4.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF1.14B $
CapEx (TTM)459.78M $
FCF Margin11.93%
FCF Yield14.62%
Net Debt9.75B $
Net Debt/EBITDA5.35
Balance Sheet
Debt/Equity1.81
Current Ratio2.47
Quick Ratio0.78
Book Value/Sh8.020 EUR
Cash/Share1.031 EUR
Dividends
Fwd Div Rate0.0800 EUR
Trail. Div Rate0.0000 EUR
Div. Yield0.92%
5Y Avg Yield1.48%
Payout Ratio24.63%
Ex-Div DateJun 30, 2026
Pay Date—
Splits
Last Split2:1
Split DateJan 4, 2016
Analyst Consensus
Rating2.1 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.40 EUR
Upside (mean)+61.4%
Target Range9.000 EUR – 21.20 EUR
€9.000+61.4% to mean€21.20
# Analysts12
Ownership
Shares Out.422.36M
Float417.32M
Insiders32.15%
Institutions37.70%
Technical
SMA 509.108 (-2.0%)
SMA 20010.34 (-13.8%)
Beta1.17
S&P 52W Chg20.05%
Avg Vol (30d)2.18M
Avg Vol (10d)1.76M
Technical Indicators
RSI (14)43.7
MACD-0.0402
MACD Signal-0.0435
MACD Hist.+0.0033
BB Upper9.154 EUR
BB Middle9.008 EUR
BB Lower8.863 EUR
BB Width3.22%
ATR (14)0.2122 EUR
Vol Ratio (20d)0.87x